Zusammenfassung
Größte Gruppe der Antidementiva sind die Cholinesterasehemmer gefolgt von Memantin, das aber nur etwa halb so viel verordnet wird. In beiden Gruppen überwiegen inzwischen die Generika. Traditionelle Antidementiva (Piracetam, Ginkgoextrakt, Nicergolin) ohne gesicherten Nutzen haben ihren rückläufigen Trend fortgesetzt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
AD2000 Collaborative Group (2004): Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011): Alzheimer's disease. Lancet 377: 1019–1031
Bateman R (2015): Alzheimer's disease and other dementias: advances in 2014. Lancet Neurol 14: 4–6
Bickel H (2001): Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriat 34: 108–115
Birks J (2006): Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD00559–3
Birks J, Grimley Evans J (2006): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD00312–0
Birks J, Harvey RJ (2006): Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD00119–0
Birks JS, Grimley Evans J (2015): Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 Apr 10; 4: CD00119–1
Davies P, Maloney AJ (1976): Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 140–3
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Deutsche Gesellschaft für Neurologie (2009): S3-Leitlinie Demenzen. Internet: www.dgn.org/images/>stories/dgn/pdf/s3_leitlinie_demenzen.pdf
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group (2014): Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370: 311–321
Flicker L, Grimley Evans G (2001): Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008): Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216–223
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012): Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366: 893–903
Loy C, Schneider L (2006): Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD00174–7
McShane R, Areosa Sastre A, Minakaran N (2006): Memantine for dementia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD00315–4
Muayqil T, Camicioli R (2012): Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other demen- tias. Dement Geriatr Cogn Dis Extra 2: 546–572
National Institute for Health and Clinical Excellence (2011): NICE technology appraisal guid- ance 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal guidance 111). Internet: www. nice.org.uk/nicemedia/live/13419/53619/53619.pdf
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group (2005): Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379–2388
Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008): Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379–397
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Por- steinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators (2014): Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322–333
Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group (2012): Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11: 851–859
Winblad B (2005): Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11:169–182
Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D,
Brashear HR, Nye JS; The GAL-INT-11/18 Study Group (2008): Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70: 2024–2035
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2015). Antidementiva. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-662-47186-9_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-47185-2
Online ISBN: 978-3-662-47186-9
eBook Packages: Medicine (German Language)